Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia - PubMed (original) (raw)

Clinical Trial

Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia

Emmanuel Boselli et al. Crit Care Med. 2005 Jan.

Abstract

Objective: To determine the steady-state plasma and epithelial lining fluid concentrations of intravenous levofloxacin, 500 mg, administered once or twice daily in critically ill patients with severe community-acquired pneumonia.

Design: Prospective, open-label study.

Setting: An intensive care unit and a clinical pharmacokinetic laboratory in two university hospitals.

Patients: Twenty-four adult patients with severe community-acquired pneumonia and receiving mechanical ventilation were enrolled.

Interventions: All subjects received 1-hr intravenous infusions of 500 mg levofloxacin once or twice daily. The plasma and epithelial lining fluid levofloxacin concentrations were determined at steady-state after 2 days of therapy with high-performance liquid chromatography.

Measurements and main results: The median (interquartile range [IQR]) plasma and epithelial lining fluid peak levofloxacin concentrations were 12.6 (IQR, 12.0-14.1) and 11.9 (IQR, 8.7-13.7) mg/L, respectively, in the once-daily group and 19.7 (IQR, 19.0-22.0) and 17.8 (IQR, 16.2-23.5) mg/L in the twice-daily group, showing a pulmonary percentage penetration of >100% in both groups. The median (IQR) total body exposures were 151 (IQR, 137-174) and 416 (IQR, 406-472) mg.hr/L, respectively, in the once-daily and twice-daily groups.

Conclusions: Our results suggest that in critically ill patients who are receiving mechanical ventilation and have severe community-acquired pneumonia and creatinine clearance of >40 mL/min, the administration of 500 mg of intravenous levofloxacin once and twice daily allows for the exceeding of pharmacodynamic thresholds predictive of outcome (i.e., peak concentration to minimum inhibitory concentration ratio of >10 or area under concentration-time curve to minimal inhibitory concentration ratio of >125 hrs) both in serum and epithelial lining fluid for pathogens with minimum inhibitory concentration values of < or =1 mg/L and >1 mg/L, respectively.

PubMed Disclaimer

Cited by

Pharmacokinetics and Penetration of Sitafloxacin into Alveolar Epithelial Lining Fluid in Critically Ill Thai Patients with Pneumonia.
Paiboonvong T, Nosoongnoen W, Sathirakul K, Tangsujaritvijit V, Kaemapairoj J, Tragulpiankit P, Montakantikul P. Paiboonvong T, et al. Antimicrob Agents Chemother. 2019 Sep 23;63(10):e00800-19. doi: 10.1128/AAC.00800-19. Print 2019 Oct. Antimicrob Agents Chemother. 2019. PMID: 31405868 Free PMC article.
Pharmacokinetics of antibiotics or antifungal drugs in intensive care units.
Dufour G, Montravers P. Dufour G, et al. Curr Infect Dis Rep. 2009 Jan;11(1):14-20. doi: 10.1007/s11908-009-0003-9. Curr Infect Dis Rep. 2009. PMID: 19094820
Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients.
Setiawan E, Abdul-Aziz MH, Cotta MO, Susaniwati S, Cahjono H, Sari IY, Wibowo T, Marpaung FR, Roberts JA. Setiawan E, et al. Sci Rep. 2022 May 27;12(1):8930. doi: 10.1038/s41598-022-12627-1. Sci Rep. 2022. PMID: 35624222 Free PMC article.
Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia.
Boselli E, Breilh D, Saux MC, Gordien JB, Allaouchiche B. Boselli E, et al. Intensive Care Med. 2006 Dec;32(12):2059-62. doi: 10.1007/s00134-006-0401-5. Epub 2006 Oct 13. Intensive Care Med. 2006. PMID: 17039351 Clinical Trial.
Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.
Rodvold KA, George JM, Yoo L. Rodvold KA, et al. Clin Pharmacokinet. 2011 Oct;50(10):637-64. doi: 10.2165/11594090-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21895037 Review.

Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia - PubMed (original) (raw)